Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion

Thrombosis and Haemostasis

Volumn 91, Issue 3, 2004, Pages 497-505

  Schoots, Ivo G ^a,c   Levi, Marcel ^a   van Vliet, Arlène K ^a   Declerck, Paul J ^b   Maas, Adrie M ^a   van Gulik, Thomas M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Fibrinolysis; Intestine; Ischemia and reperfusion; Plasminogen activator; Plasminogen activator inhibitor

Indexed keywords

ALTEPLASE; FIBRIN; FIBRIN ANTIBODY; GLUCOSE; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 33H1F7; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG MECHANISM; ENTERITIS; ENTEROPATHY; FIBRIN DEPOSITION; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; INTESTINE FUNCTION; INTESTINE INJURY; INTESTINE ISCHEMIA; INTESTINE MUCOSA; INTESTINE OBSTRUCTION; MALE; MICROCIRCULATION; MICROTHROMBUS; MODULATION; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SCORING SYSTEM; THROMBOSIS;

EID: 1642343739     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-08-0529     Document Type: Article

References (48)

1. Arvidsson D, Rasmussen I, Almqvist P, et al. Splanchnic oxygen consumption in septic and hemorrhagic shock. Surgery 1991; 109: 190-7.
2. Dahn MS, Lange P, Lobdell K, et al. Splanchnic and total body oxygen consumption differences in septic and injured patients. Surgery 1987; 101: 69-80.
3. Biffl WL, Moore EE. Splanchnic ischaemia/reperfusion and multiple organ failure. Br J Anaesth 1996; 77: 59-70.
4. Pastores SM, Katz DP, Kvetan V. Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Am J Gastroenterol 1996; 91: 1697-710.
5. Meakins JL, Marshall JC. The gut as the motor of multiple system organ failure. In: Marston A, Bulkley GB, Fiddian-Green RG, Haglund UH, eds. Splanchnic Ischemia and Multiple Organ Failure. London: Edward Arnold; 1989: 339-48.
6. Levi M, de Jonge E, van der Poll T, et al. Disseminated intravascular coagulation. Thromb Haemost 1999; 82: 695-705.
7. Margaretten W, McKay DG. Thrombotic ulcerations of the gastrointestinal tract. Arch Intern Med 1971; 127: 250-3.
8. Whitehead R. Ischaemic enterocolitis: An expression of the intravascular coagulation syndrome. Gut 1971; 12: 912-7.
9. Brandt LJ, Gomery P, Mitsudo SM, et al. Disseminated intravascular coagulation in nonocclusive mesenteric ischemia: The lack of specificity of fibrin thrombi in intestinal infarction. Gastroenterology 1976; 71: 954-7.
10. Schoots IG, Levi M, Roossink EH, et al. Local intravascular coagulation and fibrin deposition on intestinal ischemia-reperfusion in rats. Surgery 2003; 133: 411-9.
11. Marder VJ, Sherry S. Thrombolytic therapy: Current status (1). N Engl J Med 1988; 318: 1512-20.
12. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312: 932-6.
13. Yamaguchi T, Saeki M, Iwasaki Y, et al. Local thrombolytic therapy for superior mesenteric artery embolism: Complications and long-term clinical follow-up. Radiat Med 1999; 17: 27-33.
14. Paloma MJ, Páramo JA, Rocha E. Endotoxin-induced intravascular coagulation in rabbits: Effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality. Thromb Haemost 1995; 74: 1578-82.
15. Krishnamurti C, Keyt B, Maglasang P, et al. PAI-1-resistant t-PA: Low doses prevent fibrin deposition in rabbits with increased PAI-1 activity. Blood 1996; 87: 14-9.
16. Munoz MC, Montes R, Hermida J, et al. Effect of the administration of recombinant hirudin and/or tissue-plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits. Br J Haematol 1999; 105: 117-21.
17. Becker RC. Reocclusion following successful thrombolysis. Emerging concepts. Cardiology 1993; 82: 265-73.
18. Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: Experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104: 1229-35.
19. Anderson JL. Why does thrombolysis fail? Breaking through the reperfusion ceiling. Am J Cardiol 1997; 80: 1588-90.
20. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-54.
21. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581-8.
22. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72.
23. Kruithof EK, Tran-Thang C, Ransijn A, et al. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
24. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, et al. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
25. Biemond BJ, Levi M, Coronel R, et al. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 1995; 91: 1175-81.
26. Montes R, Declerck PJ, Calvo A, et al. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1. Thromb Haemost 2000; 84: 65-70.
27. Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms. Biochim Biophys Acta 1997; 1337: 257-66.
28. Craane H, Emeis JJ, Lindeman J, et al. Immunoenzymehistochemical detection of fibrin microthrombi during disseminated intravascular coagulation rats. Histochemistry 1978; 57: 97-105.
29. ten Cate H, Lamping RJ, Henny CP, et al. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem 1984; 30: 860-4.
30. Elms MJ, Bunce IH, Bundesen PG, et al. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemost 1983; 50: 591-4.
31. Verheijen JH, Mullaart E, Chang GT, et al. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266-9.
32. Levi M, de Boer JP, Roem D, et al. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radio-immunoassay. Thromb Haemost 1992; 67: 111-6.
33. Verburg M, Renes IB, Meijer HP, et al. Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1037-G1047.
34. Park PO, Haglund U, Bulkley GB, et al. The sequence of development of intestinal tissue injury after strangulation ischemia and reperfusion. Surgery 1990; 107: 574-80.
35. Massberg S, Enders G, Matos FC, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999; 94: 3829-38.
36. Salter JW, Krieglstein CF, Issekutz AC, et al. Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1432-G1439.
37. Yan SF, Mackman N, Kisiel W, et al. Hypoxia/Hypoxemia-Induced activation of the proco-agulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 2029-35.
38. Gross PL, Aird WC. The endothelium and thrombosis. Semin Thromb Hemost 2000; 26: 463-78.
39. Rupin A, Martin F, Vallez MO, et al. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles. Thromb Haemost 2001; 86: 1528-31.
40. Pislaru SV, Barrios L, Stassen T, et al. Infarct size, myocardial hemorrhage, and recovery of function after mechanical versus pharmacological reperfusion: Effects of lytic state and occlusion time. Circulation 1997; 96: 659-66.
41. Ohnishi Y, Butterfield MC, Saffitz JE, et al. Deleterious effects of a systemic lytic state on reperfused myocardium. Minimization of reperfusion injury and enhanced recovery of myocardial function by direct angioplasty. Circulation 1995; 92: 500-10.
42. Levi M, ten Cate H, van der Poll T. Endothelium: Interface between coagulation and inflammation. Crit Care Med 2002; 30: S220-S224.
43. Biemond BJ, Levi M, ten Cate H, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: Effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995; 88: 587-94.
44. van der Poll T, Coyle SM, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997; 89: 3727-34.
45. Jansen PM, Boermeester MA, Fischer E, et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: Studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995; 86: 1027-34.
46. Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
47. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996; 97: 2440-51.
48. Chavakis T, Kanse SM, May AE, et al. Haemostatic factors occupy new territory: The role of the urokinase receptor system and kininogen in inflammation. Biochem Soc Trans 2002; 30: 168-73.